e invite you to join us for the Society of Surgical Oncology's 59th Annual Cancer Symposium, March 23-26, 2006, at the San Diego Marriott Hotel & Marina, in San Diego, California.

Target Audience

This program is intended for all surgeons who are involved in the treatment of patients with cancer.

Goals

The goals of this symposium are to: (1) present current approaches, developing innovations, and ongoing controversies in cancer management; and (2) contribute to the knowledge of surgeons as participants in multidisciplinary teams dedicated to the care of cancer patients.

Educational Objectives

Upon completion of this program, participants should be able to: 1) discuss the interdisciplinary management of breast cancer with an emphasis on targeted and systemic therapies, advances in surgical therapies such as lymphatic mapping and radiation therapy controversies; 2) describe the status of minimally invasive surgery in cancer care; 3) explain the evidence and controversial applications of CT/PET imaging in oncology; 4) discuss the role of molecular targeted cancer therapies; 5) describe how the practicing oncologist can become involved in clinical research; 6) describe the recent results from NIH funded cooperative group trials; and 7) explain the best practice for colon cancer screening prevention and management.

Accreditation

The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The SSO takes responsibility for the content, quality and scientific integrity of this CME activity.

SSO designates this educational activity for a maximum of 33.75 category 1 credits toward the AMA Physician's Recognition Award.

Each physician should claim only credits that he/she actually spent in the educational activity.

San Died

Accommodations and Attractions

Meeting at a Glance

The San Diego Marriott Hotel & Marina is the headquarters hotel and will house the entire meeting including all scientific sessions and exhibits. The San Diego Marriott, located at the water's edge, offers a superior level of service in a lush resort setting. It's ideally located adjacent to Seaport Village and features several restaurants and lounges, room service, and a stateof-the-art fitness center.

The San Diego Marriott is a 10 minute cab ride from San Diego International Airport.

Hotel reservations must be made through the PassKey Reservations System via the internet (www.surgonc.org) or by phone. A credit card will be required to guarantee your reservation.

For best availability, make your reservation via the internet at **www.surgonc.org**. You may also make reservations by calling (800) 266-9432. Any changes / cancellations to your reservation must be made through the PassKey Reservations System either by the internet or by phone through February 27, 2006. Please do not call the hotel directly as they will not have access to the SSO room block, PassKey Reservations System or the group rate until after February 27, 2006.

The deadline for reservations is Monday, February 27, 2006.

Hotel reservations / rate availability are not guaranteed after the room block is full or after February 27, 2006. Please register early – only a limited number of rooms are available at the hotel.

Special Airfare Discounts

SSO has arranged with United Airlines for special discounts on airfares to San Diego. Save up to 15% when your tickets are purchased at least 30 days in advance. Travel must take place between March 18-31, 2006 and some restrictions may apply. Please mention the SSO Meeting ID number (listed below) when making your airline reservations.

> To book your reservation, call SSO's official travel agency, Uniglobe Preferred Travel, at 1-800-626-0359 and after the prompt dial "0" (M-F 8:30 am – 5:30 pm CST). If you prefer you may:

> > • Book your travel online at www.uniglobepreferred.com. Scroll down and click on Rapid-Rez icon. When the booking page comes up, click on

"Sign In/New Account" in the upper left portion of the screen. Fill in your Member ID and Password or if this is your first time at the site, click on "create a new account" and then fill in the required information. Please record your Member ID and your Password for future use. Discount fares are automatically displayed and booking through this site will have a reduced agency service fee of \$15.

• Call United's toll-free number, 1-800-521-4041. Mention the SSO Meeting ID Code, 560QO, to qualify for discount fares.

In addition, Delta Air Lines offers new SimpliFaresTM; with flexible minimum stay requirements; significantly reduced fares, and lower change fees.

To make reservations, call Delta Air Lines at 1-800-221-1212 or visit www.delta.com. Be sure to include your Skymiles frequent flyer number and the Society of Surgical Oncology SkyBonus number #US479900356.

Auto Rental Discounts

Hertz Car Rental has been designated as the official car rental company. Reservations may be placed online at **www.hertz.com** or through the Hertz Meeting Sales Desk at (800) 654-2240. From within Canada call (800) 263-0600. When booking reservations through Hertz, please reference the Meeting Number CV# 025B0011 to get the qualified discounts.

Temperature

The average March temperature in San Diego ranges from 52° to 66°.

Table of Contents

Goals and Objectives $\ldots \ldots 2$
Accreditation
Hotel and Airline Info 2-3
Chairman's Message 3
Thursday Program4
Friday Program9
Saturday Program 14
Sunday Program

Scientific Program Chairman's Message

On behalf of SSO President Dr. Timothy Eberlein, the Executive Council and the Scientific Program Committee, I invite you to



attend the 59th Annual Cancer Symposium of the Society of Surgical Oncology, March 23-26, 2006 in San Diego, California.

Controversies, standards, and emerging innovations are the focus for this year's scientific meeting. From the role of molecular signatures in breast cancer to cine videos on endosurgery in gastrointestinal cancer, the future is the tar-

Dr. Nelson

get for the podium. This year's scientific program committee has done a fine job of providing a balanced perspective on topics of interest from the latest in laboratory research to the most practical in clinical standards. The program is complemented by excellent invited speakers, podium and poster abstracts, educational symposiums, and Meet-the-Professor Breakfasts.

We are honored to have an exceptional group of invited speakers, including: Bruce Stillman, M.D., American Cancer Society Lecture; James Economou, M.D., James Ewing Lecture; and Murray F. Brennan, M.D., John Wayne Clinical Research Lecture. Dr. Charles M. Balch will be honored with the Annual Heritage Award.

A record-high 489 abstracts were reviewed by specialty-based committees with 103 chosen for oral presentation and 230 selected for poster presentation. The quality was excellent; a lot to look forward to at this year's meeting. A visual tour of technical aspects of laparoscopic surgery for cancer is a highlight of this year's cine clinic.

Several excellent educational symposia and world-renowned Professors have been included in the program to encourage focused discussions on topics of interest to surgical oncologists. Finally, sessions on "Clinical Trial Highlights – 2006" and "Clinical Research and the Practicing Oncologist" should stimulate dialogue on better ways to engage community surgeons in NCI-sponsored cancer trials.

We look forward to seeing you in San Diego.

Sincerely,

Heidi Nelson, M.D. Chair, Scientific Program Committee

Zhursday, March 23

Breakfast Symposium

Advances in the Systemic Therapy and Surgical Management of Breast Cancer

6:00 – 8:00 am

Moderator: Lisa A. Newman, MD

Welcome and Overview -

Expanding and Refining Non-Operative Therapy or Breast Cancer: Where Does the Surgical Oncologist Fit In? Lisa A. Newman, MD University of Michigan Ann Arbor, MI

Systemic and Targeted Therapy for Breast Cancer: The Role Oncotyping, Herceptin, and Aromatase Inhibitors Debu Tripathy, MD University of Texas Southwestern Medical Center Dallas, TX

Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer: Who Needs the Standard Axillary Lymph Node Dissection? Hiram S. Cody, III, MD Memorial Sloan-Kettering Cancer Center New York, NY

NSABP Perspective on Neoadjuvant versus Adjuvant Chemotherapy Terry P. Mamounas, MD, MPH Aultman Cancer Center Canton, OH

Controversial Issues in Radiation Therapy for Breast Cancer Thomas Buchholz, MD University of Texas M.D. Anderson Cancer Center Houston, TX

Panel Discussion

Symposium

Molecular Targeted Cancer Therapies

8:00 - 10:00 am

Moderator: Kelly M. McMasters, MD, PhD

Welcome and Introduction

Kelly M. McMasters, MD, PhD University of Louisville Louisville, KY

Anti-angiogenic Targets for Cancer Therapy

Lee M. Ellis, MD, PhD University of Texas, M.D. Anderson Cancer Center Houston, TX

Targeting Her2/Neu for Breast Cancer Therapy

George Sledge, MD Indiana University School of Medicine Indianapolis, IN

EGFR as a Molecular Target

for Cancer Therapy Roman Perez-Soler, MD New York University School of Medicine New York, NY

In the Pipeline: New Prospects

for Targeted Cancer Therapy Edward A. Sausville, MD, PhD University of Maryland Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, MD

Discussion

Thursday, March 23

Minimally Invasive Cancer Surgery – State of the Science

8:00 - 10:00 am

Moderator: Martin R. Weiser, MD

Primary Ablation of Breast Lesions

Rache M. Simmons, MD Associate Professor of Surgery Weill Medical College of Cornell University New York, NY

Current Role of Laparoscopic Pancreatectomy

Attila Nakeeb, MD Associate Professor of Surgery Indiana University School of Medicine Indianapolis, IN

Minimally Invasive Rectal Resection Martin R. Weiser, MD Assistant Surgeon, Memorial Sloan-Kettering Cancer Center; Assistant Professor of Surgery, Weill Medical College of Cornell University New York, NY

Laparoscopic and Robotic Approaches to Prostatectomy Peter G. Schulam, MD, PhD Associate Professor, Department of Urology David Geffen School of Medicine at UCLA Los Angeles, CA

Symposium

CT-PET Imaging: Evidence-Based Indications and Controversies

10:30 am - Noon

Moderator: Seza A. Gulec, MD

Introduction Seza A. Gulec, MD

Principles of Current Technology

Edward Coleman, MD Duke University Medical Center Durham, NC

Clinical Applications Pros and Cons:

Melanoma

Douglas J. Schwartzentruber, MD Center for Cancer Care at Goshen Health System Goshen, IN

Breast

David J. Winchester, MD Northwestern University Feinberg School of Medicine, Evanston Northwestern Healthcare Evanston, IL

Gastrointestinal


Jose Guillem, MD Memorial Sloan-Kettering Cancer Center New York, NY

Future Technologies

Richard Wahl, MD Johns Hopkins PET Center Baltimore, MD

PET Imaging as a Tumor Marker

Seza A. Gulec, MD Center for Cancer Care at Goshen Health System Goshen, IN



Thursday, March 23

Breast Cancer Evolving Research and Practice Patterns

10:30 am - Noon

Moderator: Henry M. Kuerer, MD, PhD

Post-mastectomy Radiation and the Surgical Oncologist: Implications for Reconstruction Steven Kronowitz, MD

University of Texas, M.D. Anderson Cancer Center Houston, TX

Preoperative Treatment for DCIS

E. Shelley Hwang, MD University of California San Francisco San Francisco, CA **Onco-type DX: Is There Any Clinical Utility?** Terry Mamounas, MD, MPH Aultman Hospital Canton OH

Integrating Recent Landmark Systemic Therapy Data into Clinical Practice: What the Surgeon Needs to Know William J. Gradishar, MD Northwestern University Chicago, IL

Foregut Cancer – Evolving Research and Practice Interests

1:00 - 3:00 pm

Moderator: Mitchell C. Posner, MD

Introduction

Mitchell C. Posner, MD Professor and Chief University of Chicago Chicago, IL

Population Sciences Update:

Improving the Outcomes of Esophageal, Gastric and Pancreatic Cancer John D. Birkmeyer, MD GD Zuidema Professor of Surgery University of Michigan Ann Arbor, MI

Adjuvant Therapy, Neoadjuvant Therapy or Resection Only:

Gastric and Esophageal Cancer David H. Ilson, MD Associate Professor, Cornell University Medical College and Associate Attending, Memorial Sloan-Kettering Cancer Center New York, NY

Pancreatic Cancer

Peter W.T. Pisters, MD Professor of Surgery University of Texas, M.D. Anderson Cancer Center Houston, TX Minimally Invasive Surgery for Foregut Cancer – Is it the Future?

Minimally Invasive Approaches to Esophageal and Gastric Cancer Yuko Kitagawa, MD Assistant Professor Keio University School of Medicine Tokyo, Japan

The Role of Endosurgery in Foregut Cancer – The Future Has Arrived

Irving Waxman, MD Professor of Medicine, Surgery and the Cancer Research Center; Director of Endoscopy, University of Chicago Chicago, IL

Thursday, March 23

Clinical Research and the Practicing Oncologist

1:00 - 3:00 pm

Moderators: Terry Mamounas, MD and Peter W.T. Pisters, MD

Becoming an NCI-Approved Clinical Investigator

Margaret M. Mooney, MD National Cancer Institute Bethesda, MD

Working With Your IRB

Scott H. Kurtzman, MD University of Connecticut Health Center Farmington, CT Maintaining a Research Program of the Highest Quality Walt Cronin, MPH NSABP Biostatistical Center Pittsburgh, PA

Implementing Clinical Research in a Private Practice Setting Thomas G. Frazier, MD Bryn Mawr Hospital Bryn Mawr, PA

Discussion

Symposium

Advances in Nutritional Support of the Surgical Cancer Patient

3:30 - 5:30 pm

Moderator: John M. Daly, MD

Introduction - "Brief History of Immunonutrition"

John M. Daly, MD Professor of Surgery and Dean Temple University School of Medicine Philadelphia, PA

Nutrition Support:


Madison, WI

Who Benefits? Who Doesn't? Kenneth Kudsk, MD Professor of Surgery Vice Chairman of Surgical Research University of Wisconsin Role of Arginine in the Care of the Surgical Patient Adrian Barbul, MD Surgeon-in-Chief and Professor of Surgery Sinai Hospital, Johns Hopkins University Baltimore, MD

Clinical Trials of Immunonutrition

in Surgical Cancer Patients Marco Braga, MD Professor of Surgery University of Milan, San Raffaele Hospital Milan, Italy

Discussion



Thursday, March 23

Controversies in Surgical Oncology: Can We Define an Evidence Based Standard of Care?

3:30 - 5:30 pm

Moderator: Daniel G. Coit, MD

Multimodality Therapy is NOT the Standard of Care for Adenocarcinoma of the GE Junction *Pro:* Tom R. DeMeester, PhD

University of Southern California, Los Angeles, CA
Con: Mitchell C. Posner, MD
University of Chicago, Chicago, IL

The Optimal Margin of Resection

- for All Melanomas is 1 cm *Pro:* Vernon K. Sondak, MD H. Lee Moffitt Cancer Center, Tampa, FL
- *Con:* Merrick I. Ross, MD University of Texas M.D. Anderson Cancer Center Houston, TX

Completion Axillary Lymph Node Dissection is Unnecessary for Sentinel Node Positive Breast Cancer

Pro: Blake Cady, MD Rhode Island Hospital, Providence, RICon: Kelly M. McMasters, MD, PhD University of Louisville, Louisville, KY

Cancer Forum I – Signaling and Apoptosis

3:30 - 5:30 pm

Moderators: Daniel Albo, MD and James C. Cusack, Jr., MD

Nuclear Factor Kappa B Regulates Beta-Catenin Expression and Function in Human Colon Cancer Cells Christopher Smolock, MD University of Pennsylvania, Philadelphia, PA

Mechanisms of MET Dysregulation and Ligand-

Dependency in Human Colorectal Cancer T. Francone, MD Memorial Sloan-Kettering Cancer Center, New York, NY

Expression of IL-8 in Pancreatic Tumor Cells is Regulated by a Src/STAT3 Jose G. Trevino, MD University of Texas M.D. Anderson Cancer Center, Houston, TX

RON Tyrosine Kinase: A Novel Target for Enhancing Molecular Therapy in Colorectal Cancer Ashwani Rajput, MD Roswell Park Cancer Institute, Buffalo, NY Escape from Endogenous Interferon Gamma Anti-Tumor Effects by Alteration of IRF-1 and IRF-2 Responses B.D. Saunders, MD University of Michigan, Ann Arbor, MI

Tat-Bim Protein Induces Apoptosis in Cancer Cells Hiroyuki Kashiwagi, MD Washington University, St. Louis, MD

A Novel Small Molecule FAK Tyrosine Kinase Inhibitor Increases Apoptosis in Pancreatic Adenocarcinoma Cells Steven Hochwald, MD University of Florida College of Medicine, Gainesville, FL

Deregulation of JNK in Response to Chemotherapy When NF-KB is Inhibited: A Potential Target in Chemoresistant Pancreatic Cancers Hong Kin Kim, MD University of North Carolina, Chapel Hill, NC



Welcome Reception

7:30 – 9:00 pm

Join us for hors d'oeuvres, refreshments and socializing. This complimentary event will be held at the San Diego Marriott Hotel and is open to all physician registrants and registered guests.

Friday, March 24

Meet the Professor Breakfasts

6:30 - 7:30 am

Registration Required • Fee: \$35 • Limit: 25 per breakfast

Each continental breakfast will feature presenters of international prominence. To ensure your selection, please register as early as possible. Indicate your selection on the enclosed registration form.

- B1 The Significance of Positive Margins in Sarcoma Surgery Murray F. Brennan, MD
- B2 Parathyroid Surgery The Application of New Technologies Nancy D. Perrier, MD
- **B3** Sentinel Lymph Node Mapping Aberrations and Challenges in Breast Cancer Hiram S. Cody, III, MD
- B4 Cryoblation of Breast Cancer Technical Aspects Rache M. Simmons, MD

- **B5** Preserving the Aesthetic Breast: Best Practices Benjamin O. Anderson, MD Grant W. Carlson, MD
- **B6** Laparoscopic Distal Pancreatectomy Really? Mitchell C. Posner, MD
- **B7** Melanoma Optimal but Practical Nodal Management Strategies Vernon K. Sondak, MD
- B8 Surgical Education What's Next and What to Do About It David P. Jaques, MD

Opening Announcements

7:30 - 7:45 am

Timothy J. Eberlein, MD, SSO President Heidi Nelson, MD, Scientific Program Chairman Robert M. Barone, MD, Local Arrangements Chairman

Presentations from James Ewing Oncology Fellowship Award Winners

7:45 - 8:00 am

J. Pablo Arnoletti, MD Eric Nakakura, MD Sophie Dessureault, MD

Plenary Session I

8:00 - 9:00 am

Moderator: Raphael E. Pollock, MD, PhD

Surgical Complications Associated with Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection, Versus SLND Alone in the American College of Surgeons Oncology Group (ACOSOG) Trail Z0011 Anthony Lucci, MD University of Texas M.D. Anderson Cancer Center Houston, TX

Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment Sam Wiseman, MD St. Paul's Hospital, University of British Columbia Vancouver, Canada **Trends in the Treatment and Outcome of Pancreatic Cancer in the United States** Nancy Baxter, MD University of Minnesota Minneapolis, MN

An International, Randomized, Double-Blind, Phase 3 Study of the Specific Active Immunotherapy Agent, Onamelatucel-L (Canvaxin[™]), Compared to Placebo as a Post-Surgical Adjuvant in AJCC Stage IV Melanoma Donald L. Morton, MD John Wayne Cancer Institute Santa Monica, CA

Friday, March 24

Assessing the State of Surgical

Oncology: The Future is Now

9:00 - 9:45 am

Timothy J. Eberlein, MD

Department of Surgery,

Bixby Professor and Chairman

Washington University School

of Medicine, Spencer T. and Ann W. Olin Distinguished Professor,

Director, Alvin J. Siteman Cancer

Center, Surgeon-in-Chief, Barnes

-Jewish Hospital, St. Louis, MO

SSO Presidential Address

Plenary Session II

10:15 - 11:00 am

Moderator: Nicholas J. Petrelli, MD

Cyclin Dependent Kinase2-Associated Protein (CDK2-AP1) Expression and Modulation of Cell Growth and Apoptosis in Microsatellite-Unstable (MSI) Colorectal Cancer (CRC) P.V. Sreeramoju, MD Albert Einstein College of Medicine New York, NY

Oxaliplatin Resistance in Colorectal Cancer Cells Induces Epithelial-to-Mesenchymal Transition Anthony D. Yang, MD University of Texas M.D. Anderson Cancer Center Houston, TX

Clinical and Immunologic Responses in Cancer Patients with Stage IV Disease Treated with Autologous Tumor Cell-Based Vaccines Using a Universal GM-CSF Producing and CD40L-Expressing Bystander Cell Line (GM.CD40L): Early Results Sophie Dessureaulat, MD H. Lee Moffitt Cancer Center Tampa, FL

Annual Heritage Presentation Honoring Charles M. Balch, MD SSO President 1991-92

11:00 - 11:15 am

Presented by: Alfred M. Cohen, MD Director and CEO, Markey Cancer Center Lexington, KY

American Cancer Society/SSO Basic Science Lecture Genomic Applications for the Diagnosis and Treatment of Cancer



11:15 am - 12:00 Noon

Bruce Stillman, PhD, FRS President Cold Spring Harbor Laboratory Cold Spring Harbor, NY Introduction by:

Steven F. Sener, MD Past President, ACS

Lunch & Poster Session in Exhibit Area

Noon - 1:00 pm

Posters # P1 – P115 will be presented.

Friday, March 24

1:00 - 3:00 pm

These sessions will feature abstract presentations specifically related to the following areas:

Gastrointestinal Cancer

Moderators: Malcolm M. Bilimoria, MD and Mokenge P. Malafa, MD

The Prognostic Effect of Micrometastases in Previously Staged Lymph Node Negative (N0) Colorectal Carcinoma: A Meta-Analysis Douglas M. Iddings, MD John Wayne Cancer Institute Santa Monica, CA

Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, MTHFR or XRCC1 Gene? D.Y. Kim, MD Ajou University School of Medicine Suwon, South Korea

Evaluation of Preoperative Therapy for Pancreatic Cancer Using a Prognostic Nongram Rebekah White, MD Memorial Sloan-Kettering Cancer Center New York, NY

Stromal Osteonectin Overexpression is Associated with Poor Outcome in Patients with Periampullary Cancer Mark Bloomston, MD Ohio State University, Columbus, OH

Better Survival in Esophageal Cancer Patients After Surgical Treatment in University Hospitals. A Plea for Performance by Surgical Oncologists C. Verhoef MD University Medical Center Groningen Groningen, Netherlands

Single Nucleotide Polimorphisms (SNPs) in the Promoter Region of the E-Cadherin Gene in Young Patients with Diffuse Gastric Cancer Heriberto Medina-Franco, MD National Institute of Medical Sciences and Nutritio, Mexico City, Mexico

Pilot Study of Minimally Invasive Surgery for Gastric Cancer: Laparoscopic Assisted Distal Gasterectomy (LADG) K. Koneri, MD, Kameda Medical Center Kamogawa, Japan

Repeat Hepatectomy for Recurrent Colorectal Liver Metastasis: Analyses of Preoperative Prognostic Factors Seiji Ishiguro, MD National Cancer Center Hospital Tokyo, Japan

Breast Cancer

Moderators: Robert J. Goulet, Jr., MD and Amy C. Degmin, MD

Prior Axillary Surgery is Not a Contraindication to Sentinel Lymph Node Biopsy: Results of Reoperative Sentinel Lymph Node Biopsy in 133 Patients C. Garcia-Etienne, MD Memorial Sloan-Kettering Cancer Center New York, NY

Serumproteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage I Breast Cancer Claudio Belluco, M, University of Padova Padova, Italy

Detecting Occult Breast Cancer in Prophylactic Mastectomies: Sentinel Node Biopsy vs. Pre-Operative MRI D. Black, MD, Massachusetts General Hospital Boston, MA

Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Disease at Presentation E.L. Newman, MD, University of Michigan Ann Arbor, MI

Initial Outcomes for Patients Treated on the American Society of Breast Surgeons Mammo Site Clinical Trial for Ductal Carcinoma In Situ of the Breast Jacqueline S. Jeruss, MD University of Texas M.D. Anderson Cancer Center Houston, TX

Lymphedema Therapy Reduces the Volume of Edema and Pain in Breast Cancer Patients John B. Hamner, MD University of Tennessee, Memphis, TN

Prospective Randomized Trial Comparing Intradermal, Intraparenchymal, and Subareolar Injection Routes for Sentinel Lymph Node Mapping and Biopsy in Breast Cancer Stephen P. Povoski, MD Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Comprehensive Cancer Center of The Ohio State University, Columbus, OH

Is Sentinel Node Biopsy in DCIS Necessary? Thomas B. Julian, MD

NSABP Operations Office and Allegheny General Hospital Pittsburgh, PA

Friday, March 24

1:00 - 3:00 pm

These sessions will feature abstract presentations specifically related to the following areas:

Melanoma

Moderators: Kenneth K. Tanabe, MD and Sandra L. Wong, MD

Role of Micropthalamia Transcription Factor in Melanoma Prognosis and Differentiation George I. Salti, MD University of Illinois at Chicago Chicago, IL

Downregulation of Pro-Apoptosis Genes in an Early Event in the Progression of Malignant Melanoma Eric H. Jensen, MD H. Lee Moffitt Cancer Center and Research Institute Tampa, FL

Role of BAY 43-9006 in Combination with Temozolomide and and Melphalan in Metastatic Melanoma Jin Yoo, MD Duke University Medical Center

Duke University Medical Center Durham, NC AJCC Nodal Factors and Microscopic Tumor Burden

Predict Recurrence in Sentinel Lymph Node Positive Stage III Melanoma Patients Robert H. Andtbacka, MD University of Texas M.D. Anderson Cancer Center Houston, TX

Is the 10% Rule Appropriate for Sentinel Lymph Node Biopsy for Melanoma? H. Kroon, MD University of Michigan Ann Arbor, MI

Patients (pts) Prognosis and Clinico-Pathological Factors Influencing False Negative (FN) Results of Sentinel Lymph Node (SLN) Biopsy in Cutaneous Melanoma (CM) Zbigniew I. Nowecki, MD Cancer Center – Institute Warsaw, Poland

Peri-Operative Adjuvant Biotherapy for Resected Cutaneous Melanoma: An Update on 5 Years of Follow-up

John L. Zapas, MD Franklin Square Hospital Center Baltimore, MD

Intraoperative Evaluation of Sentinel Lymph Nodes for Metastatic Melanoma by Imprint Cytology V. Soo, MD Wake Forest University Winston-Salem, NC

Endocrine/Head & Neck

Moderators: John A. Olson, Jr., MD and Ashok Shaha, MD

Survival Benefit of Extensive Hepatic Cytoreduction for Symptomatic Metastases from Neuroendocrine Tumors Farin F. Amersi, MD John Wayne Cancer Institute Santa Monica, CA

Four-Dimensional Computed Tomography: A Novel Imaging Modality for Localization of Parathyroid Tumors S.E. Rodgers, MD University of Texas M.D. Anderson Cancer Center Houston, TX

Hypocalcemia in Patients Taking Imatinib Mesylate Frank J. Quayle, MD Washington University School of Medicine St. Louis, MO

Sonographically Guided Fine Needle Aspiration with Rapid Parathyroid Hormone Assay: A New Localization Technique for Remedial Parathyroid Surgery Christina L. Maser, MD Yale University New Haven, CT

Is Tumor Size the Best Predictor of Outcome for Papillary Thyroid Cancer? Y. Cheema, MD University of Wisconsin Madison, WI

Positron Emission Tomogram (PET) Detected Thyroid Incidentalomas: Need for Further Investigation? Chandrakanth Are, MD Memorial Sloan-Kettering Cancer Center New York, NY

New Parameters in Risk Stratification in Papillary Thyroid Carcinoma: Eosinophilic Infiltration, Glutathione S-Transferases and Genomic Instability Sadir Alrawi, MD Roswell Park Cancer Institute Buffalo, NY

Photodynamic Therapy for Head and Neck Neoplasia Using Photofrinin® Rosa E. Cuenca, MD Leo Jenkins Cancer Center, Brody School of Medicine East Carolina University Greenville, NC

Friday, March 24

Cancer Forum II – Translational Research

1:00 - 3:00 pm

Moderators: Jeffrey F. Moley, MD and Timothy J. Yeatman, MD

Omega- Fatty Acids Prevent Early Pancreatic Neoplasia in EL-Kras Transgenic Mice

Laleh Golkar, MD Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine Chicago, IL

Real-Time Intraoperative Imaging Using Invisible Near-Infrared Light John V. Frangioni, MD Beth Israel Deaconess Medical Center, Boston, MA

Metastasis of Papillary Thyroid Carcinoma is Associated with BRAF Gene Mutation Joseph Kim, MD John Wayne Cancer Center, Santa Monica, CA

Correlation of Breast Cancer Protein and Gene Expression Profiles with ER Status Susanna H. Shin, MD Eastern Virginia Medical School, Norfolk, VA **Photodynamic Therapy for Treatment of Self-expandable Metal Stent Luminal Obstruction** Rosa E. Cuenca, MD Leo Jenkins Cancer Center, Brody School of Medicine and Physics Department, East Carolina, Greenville, NC

Dynamic Contrast Magnetic Resonance Imaging Detects Premalignant High-Grade Dysplasia in Epithelian Carcinogenesis Via Identification of Enhanced Microvascular Permeability Jeffrey M. Arbeit, MD Washington University in St. Louis, St. Louis, MO

Imaging the Role of Splenocytes

in Promoting Liver Metastases Michael Bouvet, MD University of California San Diego, San Diego, CA

Poster Discussion Session (Posters #P1 – P115)

3:00 - 4:00 pm

This session will encourage meaningful discussion and constructive critique of recent research findings. Over 100 posters will be displayed. Authors will be present.

Symposium

What's New in Ablative Therapies for Malignant Tumors

4:00 - 6:00 pm

Moderator: Michael Choti, MD

Indications and Evidence for Radiofrequency Ablation of Liver Tumors Anton Bilchik, MD John Wayne Cancer Institute Santa Monica, CA

Microwave Ablation: The Next Modality?

David M. Mahvi, MD University of Wisconsin Madison, WI Ablative Approaches to Pulmonary, Renal and Bone Tumors Robert G. Martin, MD University of Louisville Louisville, KY

Where Do We Go from Here? Improving Targeting and Monitoring of Ablative Therapy Michael A. Choti, MD Johns Hopkins University School of Medicine Baltimore, MD

Case Presentations and Panel Discussion

Friday, March 24

Clinical Trials Highlights 2006

4:00 - 6:00 pm

Moderator: Margaret Mooney, MD

Introduction and Update on NCI Trial Priorities

Margaret Mooney, MD National Cancer Institute Bethesda, MD

Open Trials and New Concepts

Gastrointestinal Cancer Trials Heidi Nelson, MD Mayo Clinic, Rochester, MN Nicholas J. Petrelli, MD Helen F. Graham Cancer Center Newark, DE

Thoracic Cancer Trials

Leslie Kohman, MD SUNY Upstate Medical University Syracuse, NY Bryan Meyers, MD Barnes Jewish Hospital St. Louis, MO

Breast Cancer Trials Kelly K. Hunt, MD

University of Texas M.D. Anderson Cancer Center Houston, TX

Terry Mamounas, MD, MPH Aultman Cancer Center Canton, OH

Panel Discussion

Saturday, March 25

Meet the Professor Breakfasts

6:45 - 7:45 am

Registration Required • Fee: \$35 • Limit: 25 per breakfast

Each continental breakfast will feature presenters of international prominence. To ensure your selection, please register as early as possible. Indicate your selection on the enclosed registration form.

- **B9 Handoscopy: It's a Role in Colectomy** Bob Cima, MD
- B10 Adrenal Tumors Interesting Cases and Best Approaches Jeffrey E. Lee, MD
- B11 The Role of Neoadjuvant Therapy Esophageal Cancer Stephen G. Swisher, MD
- **B12 Rectal Cancer Adjuvant, Who and When?** David A. Rothenberger, MD

- **B13 Rectal Cancer Sphincter Preservation Options** Timothy J. Yeatman, MD
- B14 Colorectal Metastases New Methods for Optimal Liver Resection Bryan Clary, MD
- B15 Breast Cancer Neoadjuvant Practical Applications Lisa A. Newman, MD

Saturday, March 25

Plenary Session III

8:00 - 9:00 am

Moderator: William G. Cance, MD

Endoscopic Ultrasound-guided Fine Needle Aspiration of Visible Celiac Nodes is Essential for Determining Prognosis in Patients with Distal Esophageal Cancer: A Survival Analysis in 71 M1a Patients Eric Frechetti, MD Laval Hospital, Quebec, Canada

A Phase II Trial of Bevacizumab with or without Low-Dose Interferon-alpha in Patients with Metastatic Malignant Melanoma Kimberly A. Varker, MD The Ohio State University Comprehensive Cancer Center Columbus, OH Feasibility of Sentinel Lymph Node in Differentiated Thyroid Carcinoma Paolo Carcoforo, MD Sant'Anna Hospital Ferrara, Italy

Correlation of Bone Marrow Micrometastases with Sentinel Lymph Node Status in 410 Early Stage Breast Cancer Patients Igor Langer, MD Swiss Multicenter Study Group Sentinel Lymph Node in Breast Cancer Basel, Switzerland

James Ewing Lecture

Surgical Oncology in the Genome Era



9:00 – 9:45 am

James S. Economou, MD, PhD Director, UCLA Human Gene Medicine Program, Deputy Director, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles Los Angeles, CA

Plenary Session IV

10:15 - 11:15 am

Moderator: Fabrizio Michelassi, MD

Factors Associated with Treatment Failure in T1bN0 Breast Cancer Patients Timothy J. Kennedy, MD Northwestern University Chicago, IL

Phase II Study o Imatinib Mesylate in Patients with Metastatic Medullary Thyroid Carcinoma (MTC): An Interim Analysis Mark S. Cohen, MD Washington University School of Medicine Alvin J. Siteman Cancer Center St. Louis, MO EGF Pathway Activation in Hepatocellular Carcinoma is a Prognostic Predictor of Survival and a Potential Target for Biologic Therapy Jason M. Foster, MD Roswell Park Cancer Institute Buffalo, NY

High-Resolution Positron Emission Mammography in Breast Cancer Zandra H. Cheng, MD Anne Arundel Medical Center Annapolis, MD

Saturday, March 25

John Wayne Clinical Research Lecture Lessons Learned from 30 Years of Clinical Research

11:15 am - 12:00 Noon



Murray F. Brennan, MD Chairman, Department of Surgery Memorial Sloan-Kettering Cancer Center New York, NY Lunch & Poster Session in Exhibit Area

Noon - 1:00 pm

Posters # P116 - P230 will be presented.

Cancer Forum III – Immune and Gene Therapy

1:00 – 3:00 pm

Moderators: David C. Linehan, MD and George E. Peoples, Jr., MD

NBL1: A Novel Methylation Target in Colon Cancer Quan P. Ly, MD Moffitt Cancer Center & Research Institute Tampa, FL

Creation and Validation of a Novel Herpes Simplex Virus with Diagnostic and Therapeutic Potential in Pancreatic Cancer

James J. Mezhir, MD University of Chicago Chicago, IL

Tumor Selective Vaccinia Mutant is Effective in the Treatment and Prevention of Peritoneal Carcinomatosis in a Mouse Model Sricharan Chalikonda, MD Cleveland Clinic Foundation Cleveland, OH

Involvement of Bcl Gene Family Members in Anti-4-1BB-Induced T Cell Survival and Antitumor Reactivity Hidde M. Kroon, MD University of Michigan Ann Arbor, MI Nanoscale Platform for Radioinducible Gene Therapy Hank Schmidt, MD University of Chicago Chicago, IL

Targeting and Bioluminescence Imaging of a Novel Herpes Simplex Virus is Dependent on Tumor MEK Activity Kerrington Smith, MD University of Chicago Chicago, IL

Activated Murine Liver Plasmacytoid Dendritic Cells are Able to Stimulate NK Cells and T Cells T. Peter Kingham, MD Memorial Sloan-Kettering Cancer Center New York, NY

The Therapeutic value of Protein Monoclonal Antibodies Directed Against Immunogenic Tumor Glycoproteins Myron Arlen, MD North Shore University Hospital Manhasset, NY

Saturday, March 25

1:00 - 3:00 pm

These sessions will feature abstract presentations specifically related to the following areas:

Gastrointestinal Cancer

Moderators: Philip B. Paty, MD and Jean-Nicolas Vauthey, MD

Armless Navigation and Image-guidance During Abdominal Exploration for Recurrent Colorectal Cancer

Ergun Kocak, MD Ohio State University Columbus, OH

Adjuvant Radiation Therapy Improves

Survival for Gallbladder Carcinoma Pablo Mojica, MD City of Hope National Medical Center Duarte, CA

Loss of MAL Expression in Precancerous (Dysplastic) Lesion of the Esophagus Koshi Mimori, MD

Medical Institute of Bioregulation, Kyushu University Beppu, Japan

Gene Expression Profiling of Gastric Cancer Reveals a Lymph Node Metastatic Transcriptional Fingerprint Claudio Belluco, MD University of Padova Padova, Italy

Lymphadenectomy for Adenocarcinoma

of the Gastroesophageal Junction Andrew P. Barbour, MD Memorial Sloan-Kettering Cancer Center New York, NY

mTOR Inhibition Potentiates Cytotoxic Therapy Against Pancreatic Cancer Through Tumore Vessel Thrombosis and Inhibition of Hypoxia-Inducible Factor-1 Koji Fujimoto, MD Kyoto University, Kyoto, Japan

Recurrence of Pseudomyxoma Peritonei After Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: Location, Treatment, and Outcome Robert Smeenk, MD The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital Amsterdam, Netherlands

Carcinoid of the Rectum Risk Stratification (CaRRS): A New Strategy for Preoperative Outcome Assessment Bridget N. Fahy, MD Memorial Sloan-Kettering Cancer Center, New York, NY

Breast Cancer

Moderators: Kelly K. Hunt, MD and David 7. Winchester, MD

Frequency of BRCA1 and BRCA2 Genomic Rearrangements and Mutations in Men with Breast Cancer: A Clinic-based Study in the United States Julia Tchou, MD University of Pennsylvania Philadelphia, PA

Lymph Node Metastatic Fingerprint Revealed by Genome-Wide Transcriptional Profiling of Primary Breast Cancer Claudio Belluco, MD University of Padova Padova, Italy

Characteristics and Treatment of Metaplastic Breast Cancer: Analysis of 892 Cases from the National Cancer Data Base Christopher M. Pezzi, MD Abington Memorial Hospital Abington, PA

Type and Duration of Exogenous Hormone Use Does Not Affect Receptor Status when Breast Cancers Develop Anjali S. Kumar, MD University of California San Francisco San Francisco, CA

How Many Sentinel Nodes Should be Removed in Breast Cancer? Michael S. Sabel, MD University of Michigan Ann Arbor, MI

Upstaging and Improved Survival of Early Breast Cancer Patients after Implementation of Sentinel Node Biopsy for Routine Axillary Staging Kimberly Vanderveen, MD University of California – Davis Sacramento, CA

Results of MRI Screening for Breast Cancer in High Risk Patients with LCIS and Atypical Ductal Hyperplasia Elisa R. Port, MD Memorial Sloan-Kettering Cancer Center New York, NY

Conflicts in Decision-Making for Breast Cancer Surgery Diane M. Opatt, MD Fox Chase Cancer Center, Philadelphia, PA

Saturday, March 25

1:00 - 3:00 pm

These sessions will feature abstract presentations specifically related to the following areas:

Sarcoma

Moderators: Samuel Singer; MD and Sam S. Yoon, MD

Use of Tissue Expanders and Preoperative External Beam Radiotherapy in the Treatment of Retroperitoneal Sarcoma Jonathan S. White, MD Tom Baker Cancer Centre Calgary, Canada

Neoadjuvant Gleevec is Effective in the Treatment of High-risk Gastrointestinal Stromal Tumors Cletus Arciero, MD Fox Chase Cancer Center Philadelphia, PA

Retroperitoneal and Truncal Sarcomas: Prognosis Depends Upon Type Not Location E.A. Perez, MD University of Miami Miami, FL

Outcome of Metastatic GIST in the Era Before Imatinib Mesylate Jason S. Gold, MD Memorial Sloan-Kettering Cancer Center New York, NY

A 30 Year Review of Primary Breast Sarcomas

Evaluated at a Single Institution Ying Wei Lum, MD Johns Hopkins Baltimore, MD

Lymph Drainage Pattern of the Peritoneal Space: Intraperitoneal Lymph Travels via Visceral Bowel Lymphatics to the Thoracic Duct Cherie P. Parungo, MD Brigham & Women's Hospital Boston, MA

Hepatectomy and Lung Radiofrequency Ablation for Hepatic and Subsequent Pulmonary Metastases from Colorectal Carcinoma Tristan D. Yan, MD St. George Hospital Sydney, Australia

Thoracoscopic Localization's Techniques for Patients with Lung Cancer Davide Sortini, MD University of Ferrara Ferrara, Italy

Outcomes/Surgical Specialties

Moderators: Tara Breslin, MD and Larissa Temple, MD

Validation of a Predictive Model for Sentinel Lymph Node Metastases in Melanoma Michael S. Sabel, MD University of Michigan Ann Arbor, MI

Size of Metastasis in the Sentinel Node Predicts Additional Nodal Involvement in Penile Carcinoma Bin Kroon, MD The Netherlands Cancer Institute Amsterdam, Netherlands

DOD Award: Phase I Trial of Anti-prostate Cancer Therapy via Anti-PSMA Designer T Cell Autografting Richard P. Junghans, MD Boston University School of Medicine

Roger Williams Medical Center Providence, RI

Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer Marianne K. Lange, MD Spectrum Health/Michigan State University Grand Rapids, MI

Advanced Generation Anti-CEA Designer T Cell Therapy of Adenocarcinoma Richard P. Junghans, MD Boston University School of Medicine Roger Williams Medical Center Providence, RI

Impact of Surgical Palliation on Quality of Life in Patients with Advanced Malignancy: Results of the Decision and Outcome in Palliative Surgery (DOPS) Trial Yale D. Podnos, MD City of Hope National Medical Center Duarte, CA

A Systematic Review of Deep Venous Thrombosis Prophylaxis in Cancer Patients: Implications for Improving Quality Michael J. Leonardi, MD UCLA, Los Angeles, CA

Teaching Palliation and End of Life Care: A Core Curriculum for Surgical Residents D.D. Klaristenfeld, MD Brown University Providence, RI

Saturday, March 25

Poster Discussion Session (Posters #P116 – P230)

3:00 - 4:00 pm

This session will encourage meaningful discussion and constructive critique of recent research findings. Over 100 posters will be displayed. Authors will be present.

Clinical Affairs Committee Program

The Role of Neoadjuvant Therapy: New Perspectives and Strategies

4:00 - 5:30 pm

Moderator: Martin J. Heslin, MD


Neoadjuvant Therapy for Operable Breast Cancer: Pitfalls and Possibilities Kelly K. Hunt, MD University of Texas M.D. Anderson Cancer Center Houston, TX

Rectal Cancer: Future of Neoadjuvant Strategies

Nipun Merchant, MD Vanderbilt University Medical Center Nashville, TN Neoadjuvant Therapy in Extremity Sarcoma Peter W.T. Pisters, MD University of Texas M.D. Anderson Cancer Center Houston, TX

Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Safety and Efficacy of Focused Dose Escalation Martin J. Heslin, MD University of Alabama Birmingham, AL

Discussion



Saturday, March 25

Cine Clinic

4:00 - 5:30 pm

Moderator: N. Joseph Espat, MD

Laparoscopic Resection of a Large Mucocele with Malignant Potential Ron G. Landmann, MD Memorial Sloan-Kettering Cancer Center New York, NY

Laparoscopic Splenic Preserving Distal Pancreatectomy John H. Wang, MD

SUNY Stony Brook Stony Brook, NY

Laparoscopic Assisted Distal Gastrectomy with Lymph-Node Dissection for Early Gastric Cancer Hisakazu Hoshi, MD Kameda Medical Center Kamogawa, Japan A Combined Endoscopic and Laparoscopic Endoluminal Surgical Resection of a Proximal Gastric Gastrointestinal Stromal Tumor Eric Wallace, MD University of Iowa Iowa City, IA

Laparoscopic Palliation of Metastatic Gastric Cancer Stephanie Dunkle-Blatter, MD Geisinger Medical Center Danville, PA

Annual SSO Business Meeting

5:30 - 6:30 pm

- I. Call to Order Timothy J. Eberlein, MD
- II. President's Report Timothy J. Eberlein, MD
 - Recognition of Program Chair
 - Announce Resident Essay Winners
- III. Secretary's Report Fabrizio Michelassi, MD
 - In Memoriam
 - Introduction of New Members
- IV. Treasurer's Report William G. Cance, MD
- V. Annals of Surgical Oncology Charles M. Balch, MD

- VI. Recognition of Outgoing Councillors Timothy J. Eberlein, MD
- VII. Nominating Committee Report John M. Daly, MD
- VIII. Introduction of New President
- IX. New Business *Raphael E. Pollock*, *MD*, *PhD*2007 Annual Meeting Washington, D.C.
- X. Adjourn Raphael E. Pollock, MD, PhD

SSO President's Reception and Banquet

7:00 - 10:00 pm Registration Required • Black Tie Optional

All physicians and their registered guests are invited to attend this gala event honoring SSO President Timothy J. Eberlein, MD.

Also honored will be this year's James Ewing Layman's Award winner.

Sunday, March 26

Breakfast Symposium

Multidisciplinary Management of Colorectal Cancer Metastases: Current and Emerging Trends

7:00 – 9:00 am

Moderator: Anton Bilchik, MD

Expanding the Criteria for Hepatic Resection:

Are Old Criteria Obsolete? Yuman Fong, MD Professor Surgery Memorial Sloan-Kettering Cancer Center New York, NY

Multimodal Therapy in Downstaging Hepatic Metastases and Improving Resectability

Jean-Nicolas Vauthey, MD Professor of Surgery University of Texas M.D. Anderson Cancer Center Houston, TX

A New Era of Effective Chemotherapeutic and Biologic Agents in Metastatic Colorectal Cancer Lee Rosen, MD Premiere Oncology and the John Wayne Cancer Institute Santa Monica, CA

Tailoring Chemotherapy in Metastatic Colorectal Cancer Using Molecular Profiling. Are We There Yet?

Robert Diasio, MD Professor Medical Oncology, University of Alabama Birmingham, AL

Discussion

Clinical Update in Colon Cancer

9:00 – 11:00 am

Moderator: Elin Sigurdson, MD

Introduction Elin Sigurdson, MD

Primary Prevention and Screening for Colorectal Cancer in the General Population Monica M. Bertagnolli, MD Brigham and Women's Hospital

Boston, MA

Screening and Management of Patients with a Familial Risk for Colorectal Cancer Jose G. Guillem, MD Memorial Sloan-Kettering Cancer Center New York, NY

Management of the Malignant Polyp in the Colon and Rectum Santhat Nivatvongs, MD Mayo Clinic Rochester, MN

Prognosis of the Patient with Colon Cancer Hartley S. Stern, MD University of Ottawa Ottawa, Canada

Adjourn – 11:00 am